Metal ion leachates and the physico-chemical stability of biotherapeutic drug products.

abstract：:Obesity, insulin resistance, glucose intolerance/type 2 diabetes and hypertension are clustered in the metabolic syndrome representing critical risk factors for increased incidence cardio-cerebro-vascular diseases, kidney failure and cancer. Ectopic fat accumulation, i.e., accumulation in the mediastinum, liver and th...

journal_title：Current pharmaceutical design

authors： Sironi AM,Sicari R,Folli F,Gastaldelli A

更新日期：2011-01-01 00:00:00

abstract：:The current gold standard for imaging infection is radiolabeled white blood cells. For reasons of safety, simplicity and cost, it would be desirable to have a receptor-specific ligand that could be used for imaging infection and that would allow a differential diagnosis between sterile and septic inflammatory processe...

journal_title：Current pharmaceutical design

authors： Chianelli M,Boerman OC,Malviya G,Galli F,Oyen WJ,Signore A

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Central serous chorioretinopathy (CSC) is the fourth most frequent retinal disorder in terms of prevalence. It typically occurs in young subjects and affects men more often than women. CSC is characterized by serous retinal detachment (SRD) involving mainly the macular area. The clinical course is usually se...

journal_title：Current pharmaceutical design

authors： Iacono P,Toto L,Costanzo E,Varano M,Parravano MC

更新日期：2018-01-01 00:00:00

abstract：:Deubiquitinating enzymes (DUBs) remove ubiquitin and ubiquitin-like modifications from proteins and they have been known to contribute to processes relevant in microbial infection, such as immune responses pathways. Numerous viral and bacterial DUBs have been identified, and activities of several host DUBs are known t...

journal_title：Current pharmaceutical design

authors： Nanduri B,Suvarnapunya AE,Venkatesan M,Edelmann MJ

更新日期：2013-01-01 00:00:00

abstract：:Reduction strategies of blood pressure, as a modifiable cardiovascular risk, are currently based on office assessment of brachial artery blood pressure. However, antihypertensive treatment based on brachial BP values reduces cardiovascular risk but cannot completely reverse the hypertension-induced risk of morbidity e...

journal_title：Current pharmaceutical design

authors： Rinaldi ER,Yannoutsos A,Borghi C,Safar ME,Blacher J

更新日期：2015-01-01 00:00:00

abstract：:The concept of probiotics has evolved immensely since it was first proposed a century ago. There are numerous potential health benefits attributed to certain probiotic bacteria, from preventing gastrointestinal (GI) infections to stimulating the immune system. Recent evidence is now quite compelling for a role of prob...

journal_title：Current pharmaceutical design

authors： O'Sullivan DJ

更新日期：2008-01-01 00:00:00

abstract：:Agomelatine markedly differs from other classes of antidepressant drugs: its primary molecular targets in vivo are the melatonin MT(1) and MT(2) receptors, where it acts as a potent agonist, and the 5-HT(2C) receptors, where it exerts clear-cut antagonist properties. Agomelatine across a wide range of clinical trials ...

journal_title：Current pharmaceutical design

authors： Bourin M,Prica C

更新日期：2009-01-01 00:00:00

abstract：:New biopharmaceutical molecules, potentially able to provide more personalized and effective treatments, are being identified through the advent of advanced synthetic biology strategies, sophisticated chemical synthesis approaches, and new analytical methods to assess biological potency. However, translation of many o...

journal_title：Current pharmaceutical design

authors： Munsell EV,Ross NL,Sullivan MO

更新日期：2016-01-01 00:00:00

abstract：:The signal transducer and activator of transcription 3 (STAT3) transduces stress signals from the plasma membrane to the nucleus but has recently also been identified in mitochondria. Inhibition of cardiomyocyte mitochondrial STAT3 with the STAT3-specific inhibitor Stattic decreases ADP-stimulated respiration and enha...

journal_title：Current pharmaceutical design

authors： Boengler K,Ungefug E,Heusch G,Schulz R

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Despite the introduction of new antiepileptic drugs (AEDs), the quality of life and therapeutic response for patients with epilepsy remain unsatisfactory. In addition, whilst several antiepileptic drugs (AEDs) have been approved and consequently marketed in recent years, little is known about their long-term...

journal_title：Current pharmaceutical design

authors： Palleria C,Cozza G,Khengar R,Libri V,De Sarro G

更新日期：2017-01-01 00:00:00

abstract：:Innate and adaptive immunity has been shown to be critically involved in the pathogenesis of atherosclerosis. In particular, immune suppression mediated by regulatory T cells (Tregs) or tolerogenic dendritic cells (DCs) serves as a vital mechanism for regulating pathogenic chronic inflammation in atherogensis, suggest...

journal_title：Current pharmaceutical design

authors： Sasaki N,Yamashita T,Kasahara K,Takeda M,Hirata K

更新日期：2015-01-01 00:00:00

abstract：:The skin remains an attractive area for drug delivery. The skin, however, often limits the ingress of drugs, because of its very low permeability. Much research, focusing on employing a variety of physical and chemical methods, aimed at reversibly altering skin permeability in favour of compounds, has been reported. O...

journal_title：Current pharmaceutical design

authors： Kilian D,Shahzad Y,Fox L,Gerber M,Du Plessis J

更新日期：2015-01-01 00:00:00

abstract：:Aberrant expression of chemokines and their receptors play causative roles in the pathophysiology of numerous autoimmune and inflammatory disease processes. Moreover, an integral step in HIV infection involves binding to chemokine receptors, and hence chemokines are intimately linked to HIV-related diseases. Therefore...

journal_title：Current pharmaceutical design

authors： Rajarathnam K

更新日期：2002-01-01 00:00:00

abstract：:Statins effectively reduce cardiovascular disease (CVD) morbidity and mortality. However, even after low-density lipoprotein cholesterol goal attainment there is a residual CVD risk. To reduce this risk, combining statins with drugs acting on the renin-angiotensin system (RAS) was investigated. The GREek Atorvastatin ...

journal_title：Current pharmaceutical design

authors： Athyros VG,Katsiki N,Karagiannis A,Mikhailidis DP

更新日期：2014-01-01 00:00:00

abstract：:The prevalence of hypertension (HTN) worldwide is high and is constantly rising. HTN is considered to be a silent killer since often there are no obvious symptoms but long-term, HTN significantly increases the risk of coronary heart disease and cerebrovascular diseases. Those with diagnosed HTN or at high risk of its ...

journal_title：Current pharmaceutical design

authors： Rysz J,Franczyk B,Banach M,Gluba-Brzozka A

更新日期：2017-01-01 00:00:00

abstract：:Alzheimer's disease (AD) is a complex degenerative disorder of the brain, associated with a progressive cognitive decline. Age is the main risk factor with almost half of the population above 90 years affected by this pathology. AD and brain aging share common molecular changes, so it has been hypothesized that AD cou...

journal_title：Current pharmaceutical design

authors： Casoli T,Balietti M,Giorgetti B,Solazzi M,Scarpino O,Fattoretti P

更新日期：2013-01-01 00:00:00

abstract：:Unlike other neuroinflammatory disorders, like Parkinson's disease, Huntington's disease and multiple sclerosis, little is still known of the role of the endocannabinoid system in Alzheimer's disease (AD). This is partly due to the poor availability of animal models that are really relevant to the human disease, and t...

journal_title：Current pharmaceutical design

authors： Bisogno T,Di Marzo V

更新日期：2008-01-01 00:00:00

abstract：:Immunosenescence is considered a major contributory factor to the increased frequency of morbidity and mortality among elderly. On the other hand centenarians are considered the best example of successful ageing. To gain insight into mechanisms of immunosenescence and its clinical relevance, a possible model is repres...

journal_title：Current pharmaceutical design

authors： Colonna-Romano G,Buffa S,Bulati M,Candore G,Lio D,Pellicanò M,Vasto S,Caruso C

更新日期：2010-01-01 00:00:00

abstract：:Over the last decade, much was learned about the biology of several types of stem and progenitor cells. It has become apparent that various cell sources may have the capacity to promote cardiomyogenesis and new blood vessel formation through different mechanisms, forming the rationale for cell-based therapy in patient...

journal_title：Current pharmaceutical design

authors： Rodrigo SF,Ramshorst Jv,Beeres SL,Bax JJ,Schalij MJ,Atsma DE

更新日期：2011-10-01 00:00:00

abstract：:The acid-base balance of cells is related to the concentration of free H⁺ ions. These are highly reactive, and their intracellular concentration must be regulated to avoid detrimental effects to the cell. H⁺ ion dynamics are influenced by binding to chelator substances ('buffering'), and by the production, diffusion a...

journal_title：Current pharmaceutical design

authors： Hulikova A,Harris AL,Vaughan-Jones RD,Swietach P

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Heat shock proteins are powerful endogenous cytoprotective proteins which help cells to survive recurrent cellular stress events. Identifying the underlying molecular mechanisms and molecular targets is especially interesting since it may help to develop new therapeutic strategies for the treatment of diseas...

journal_title：Current pharmaceutical design

authors： Golenhofen N,Bartelt-Kirbach B

更新日期：2016-01-01 00:00:00

abstract：:Metabolic syndrome (MetS) which is caused by poor dietary habits and sedentary behavior is a serious global health problem. MetS is a cluster of risk factors, represented by central obesity, hyperglycemia, dyslipidemia, and hypertension. In the 21st century, MetS and associated comorbidities, including obesity, diabet...

journal_title：Current pharmaceutical design

authors： Korivi M,Liu BR

更新日期：2020-01-01 00:00:00

abstract：:The majority of pharmaceutical formulations for the treatment of ocular pathologies are for topical administration. However, this kind of ophthalmic formulations has disadvantages such as low bioavailability and, consequently, a reduced therapeutic effect. This happens due to the anatomical and physiological specifici...

journal_title：Current pharmaceutical design

authors： Almeida H,Amaral MH,Lobao P,Frigerio C,Sousa Lobo JM

更新日期：2015-01-01 00:00:00

abstract：:Neuromuscular blocking agents are the leading drugs responsible for immediate hypersensitivity reactions during anaesthesia. Most hypersensitivity reactions represent IgE-mediated allergic reactions. Their incidence is estimated to be between 1 in 3,000 to 1 in 110,000 general anaesthetics. However striking variations...

journal_title：Current pharmaceutical design

authors： Mertes PM,Aimone-Gastin I,Guéant-Rodriguez RM,Mouton-Faivre C,Audibert G,O'Brien J,Frendt D,Brezeanu M,Bouaziz H,Guéant JL

更新日期：2008-01-01 00:00:00

abstract：: ...

journal_title：Current pharmaceutical design

authors： Deb PK

更新日期：2019-01-01 00:00:00

abstract：:A wide range of peptides and polypeptides can be appended to either the N- or C-terminus of G protein-coupled receptors without disrupting substantially ligand binding and signal transduction. Following fusion of fluorescent proteins, reporter gene constructs or G protein alpha subunits to the C-terminal tail of a rec...

journal_title：Current pharmaceutical design

authors： Milligan G,Feng GJ,Ward RJ,Sartania N,Ramsay D,McLean AJ,Carrillo JJ

更新日期：2004-01-01 00:00:00

abstract：:Since the first description of putative progenitor endothelial cells mobilized from bone marrow by stimuli like ischemia and cytokines, several studies in animals have confirmed their role in neovascularization of ischemic organs. In ischemic myocardium endothelial progenitor cells can prevent cardiomyocyte apoptosis,...

journal_title：Current pharmaceutical design

authors： Balbarini A,Barsotti MC,Di Stefano R,Leone A,Santoni T

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Medical treatments are used either alone or in combination with assisted reproductive techniques for treatment of infertile patients with hypergonadotropic hypogonadism. A wide range of treatment options such as gonadotropins, aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) and the...

journal_title：Current pharmaceutical design

authors： Kalkanli A,Akdere H,Cevik G,Salabas E,Cilesiz NC,Kadioglu A

更新日期：2020-11-01 00:00:00

abstract：:In recent years several new drugs (oxcarbazepine, lamotrigine, topiramate, gabapentin, zonisamide, tiagabine, fosphenytoin, vigabatrin and felbamate) have been added to the therapeutic armamentarium against epilepsy. Some of these represent structural modifications of pre-existing compounds, others were developed with...

journal_title：Current pharmaceutical design

authors： Gatti G,Bonomi I,Jannuzzi G,Perucca E

更新日期：2000-05-01 00:00:00

abstract：:Although somewhat controversial, there is good evidence that long-distance travel in general is a risk factor for venous thromboembolism, even in the absence of other risk factors. This is probably due to effects consequent to prolonged sitting but air travel in particular may be associated with risk factors other tha...

journal_title：Current pharmaceutical design

authors： Bradford A

更新日期：2007-01-01 00:00:00